In this seminar, we will discuss the particularly striking results from our recent study of NfL in Huntington's disease and why we think it has real potential to change the course of therapeutic development in HD and other neurogenerative diseases.
Join our CEO Kevin Hrusovsky, Dr. Jessica Gill (NIH) and Dr. Henrik Zetterberg (University of Gothenburg) as they discuss how Simoa Technology uses ultrasensitive biomarker assays to enable precision health with case studies in neurodegeneration and neurotrauma.
Miriam Moscovitch-Lopatin, from MassGeneral Institute for Neurodegenerative Disease presented a longitudinal pre-cell biomarker study she conducted on an ultrasensitive Simoa immunoassay for quantifying BDNF levels in cerebral spinal fluid in early Huntington's disease at the inaugural Powering P
Alison Joyce from Pfizer, Inc. presented her research on the development of a sensitive homebrew Simoa assay to detect Leucine-rich repeat Kinase 2 (LRRK2) at the inaugural Powering Precision Health Summit 2016.
TBIs are common in military personnel and civilians, placing these individuals at high risk for neurological deficits. The reasons why some individuals are at higher risk for these symptoms and deficits remains largely unknown. This webinar explores the topic further.